Stacie Dusetzina, Vanderbilt professor of health policy and cancer research, in a recent interview published on The Incidental Economist blog offers her take on drug policy issues.
Liam Bendicksen, a Brown University undergraduate studying public health and public policy, conducted the interview.
Dusetzina said it’s important to “balance access and innovation” in regulatory decisions.
“The trick is how to make sure the drugs that we lose if we cut spending are not the highly innovative drugs,” she said. “I think this is possible if we use the relative value of a drug to set a price that reflects the advances that the product brings to patients with a particular disease.”
To read the full interview on The Incidental Economist, click here.
